Stentys Begins APPOSITION III Study

December 9, 2010—Stentys, Inc. (Princeton, NJ) announced that it has begun the international APPOSITION III study of its self-apposing stent. Fifty patients have been enrolled, with a total expected enrollment of 500 patients. The trial primary's endpoint is major adverse cardiac events at 12 months postprocedure.

According to the company, the self-apposing stent fits into the contour of a blood vessel, and its shape and diameter adapt to the anatomic changes of the coronary arteries after acute myocardial infarction.

In the APPOSITION II randomized trial, the Stentys device was compared with a conventional, market-leading stent in patients experiencing a heart attack. The study showed that 3 days after an acute myocardial infarction, 28% of patients who were treated with conventional stents displayed significant malapposition. In contrast, none of the patients who were treated with the Stentys device had stent malapposition, stated the company.